



Françoise BERNAUDIN

Françoise Bernaudin, MD, is board-certified in Pediatrics and Pediatric Hematology and is the former Head of the Sickle Cell Reference Center at CHIC Hospital, Creteil, France. Dr Bernaudin research expertise include the epidemiology and treatment of cerebral vasculopathy in SCD and the role of hematopoietic stem-cell transplantation (HSCT) in the management of this disease. She has presented the French results of HSCT for SCD in plenary session at ASH meeting in 2002 and participated in the ASH Guideline Panel for the guidelines on stem cell transplantation for SCD (2016-2020). She is the principal investigator on a prospective French national study comparing early matched-sibling stem cell transplantation to standard-care in patients with abnormal velocities on Transcranial Doppler (“DrepaGrefe” [ClinicalTrials.gov: NCT 01340404](https://clinicaltrials.gov/ct2/show/study/NCT01340404) and [NCT 05053932](https://clinicaltrials.gov/ct2/show/study/NCT05053932)). The results of this trial at 1 and 3 years have been presented in presidential session at 2018 EBMT meeting and published in *JAMA* 2019. A new assessment is still ongoing. Dr Bernaudin is an active member of several international societies (ASH, SFH, SFGM-TC, EBMT). She is the President of the association “DREPAGREFFE” created in 2016 in order to promote hematopoietic stem cell transplantation for patients with sickle cell disease. Dr Bernaudin as authored or co-authored 129 articles in international peer-reviewed journals with 13,071 citations and an *H*-index of 52.